§ Mr. Murphyasked the Secretary of State for Social Services what representations he has received from pharmaceutical companies regarding the Greenfield report; and if he will make a statement.
§ Mr. Kenneth ClarkeIn addition to discussions which my right hon. Friend and I have had with representatives of the Association of the British Pharmaceutical Industry, several companies have written to the Department to argue that, if the recommendation on generic substitution were to be adopted, it could have serious consequences for research-based pharmaceutical companies, including reduced funds for investment in R and D, loss of export earnings and fewer jobs.